Two Directors at Antero Resources Corp sold after exercising options/sold 34,667 shares at between 38.130USD and 39.330USD. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by a...
A director at Comstock Resources Inc sold 48,915 shares at 21.205USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Victoria’s Secret & Co. Reports 2025 Fourth Quarter and Full Year Results Fourth Quarter and Full Year Results Exceeded Top- and Bottom-line GuidanceComparable Sales Increased 8% in the Fourth Quarter and 5% for the Full YearFourth Quarter and Full Year Adjusted Operating Income Significantly Exceeded ExpectationsInitiates First Quarter and Fiscal 2026 Guidance REYNOLDSBURG, Ohio, March 05, 2026 (GLOBE NEWSWIRE) -- Victoria’s Secret & Co. (“VS&Co” or the “Company”) (NYSE: VSCO) today reported financial results for the fourth quarter and fiscal year ended January 31, 2026. Hillary Super,...
HII’s Ingalls Shipbuilding Authenticates Keel of Philadelphia (LPD 32) PASCAGOULA, Miss., March 03, 2026 (GLOBE NEWSWIRE) -- HII’s (NYSE: HII) Ingalls Shipbuilding division authenticated the keel today for the future USS Philadelphia (LPD 32), a Flight II San Antonio-class amphibious transport dock ship. The ceremony included ship sponsor Maureen Paparo, a Philadelphia native, who was joined by her spouse, Adm. Samuel Paparo, commander U.S. Indo-Pacific Command. Also, attending the ceremony was Chris Kastner, HII’s president and CEO, Brian Blanchette, Ingalls Shipbuilding president and k...
A director at Northrop Grumman Corp sold/sold after exercising options 873 shares at 745.000USD and the significance rating of the trade was 92/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...
A director at Hanover Insurance Group Inc sold 1,200 shares at 180.910USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
A director at Independent Bank Corp Mi bought 1,200 shares at 35.270USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Moody's Ratings (Moody's) affirmed Pilgrim's Pride Corporation's ("Pilgrim's") Ba2 Corporate Family Rating ("CFR"), Ba2-PD Probability of Default Rating, Ba2 senior unsecured notes rating, and (P)Ba2 senior unsecured shelf rating. The speculative grade liquidity rating is unchanged at SGL-1. We revi...
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evor...
Chemed Reports Fourth-Quarter 2025 Results CINCINNATI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its fourth quarter ended December 31, 2025, versus the comparable prior-year period. Results for Quarter Ended December 31, 2025 Consolidated operating results: Revenue was $639.3 million, essentially flat with the...
Moody's Ratings (Moody's) said that Gilead Sciences, Inc.'s ("Gilead"; A3 positive) acquisition of Arcellx will improve Gilead's product and therapeutic diversity through full ownership of its key cell therapy pipeline product anito-cel for multiple myeloma. Gilead announced on 23 February that it e...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.